raise 8M€ to support the development of its MVdeltaC immunotherapeutic vaccine in oncology
Summary
This technology has already been successfully used to develop 6 prophylactic vaccines tested in human clinical trials, notably for immunogenicity.MVdeltaCs immuno-oncolytic efficacy has already been widely demonstrated in multiple in-vitro and in-vivo tumor models, and its unique mechanism of action has been documented and published in the international scientific literature. Preclinical pharmacological and regulatory safety trials on MVdeltaC are currently being finalized.The promising results of MVdeltaC were presented at the International Society for Vaccines (ISV) Congress held from October 22 to 24, 2023 in Lausanne, Switzerland.Oncovita, a spin-off from Institut Pasteur, is a biotechnology company dedicated to the design and early development of new therapeutic and prophylactic vaccines against various types of cancer. France 2030 is in possession and has control over its 54 billion fund and will invest 50% of the budget into the decarbonisation of French economy and the latter 50% in sustainable innovations and ground-breaking technologies. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export). For more information, please visit: https://www.bpifrance.com/ Follow us on Twitter: @Bpifrance @BpifrancePresseSGPI / Agence de linnovation en sant\xe9 Florence Gaudin Florence.gaudin@pm.gouv.fr